Monte Rosa Therapeutics, Inc. (GLUE) financial statements and ratios from SEC XBRL: revenue $123.67M (TTM), net margin -31.2%, revenue growth 63.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $123.67M |
| Net Margin | -31.2% |
| Revenue Growth (YoY) | 63.5% |
| FCF Growth (YoY) | -172.3% |
| Price / Book | 2.58 |
| Price / Sales | 41.76 |
| FCF Yield | -13.2% |
| Altman Z-Score | 2.55 (grey) |
| Sector P/E (Healthcare) | 21.6 |
GLUE overview · GLUE earnings · GLUE KPIs · GLUE investor relations · GLUE ownership · GLUE peers · GLUE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.